Where Will Pfizer Stock Be in 3 Years?

The healthcare giant has been investing heavily in its future growth.
PharmExec

Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into a compelling, dominant narrative. And in capital markets, narrative coherence often drives valuation as much as scientific potential.
24/7 Wall St.

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net sales with revenue up 10% year over year, powered by a post-Humira immunology rebuild that is now clearly working.

Pfizer Could Surprise Again This Earnings Season (Preview)

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more about PFE stock here.